Localization of Intramuscular mRNA Delivery using Deep Eutectic-Lipid Nanocomposites
This article is protected by copyright. All rights reserved.PMID:38693774 | DOI:10.1002/adhm.202400327 (Source: Cancer Control)
Source: Cancer Control - May 2, 2024 Category: Cancer & Oncology Authors: A M Curreri M Dunne G Bibbey N Kapate J Kim S Mitragotri Source Type: research
Cancer Nanovaccines: Nanomaterials and Clinical Perspectives
This review provides detailed insight into cancer nanovaccines. It examines current developments, innovative strategies, and technologies, encompassing preclinical/clinical advancements. Key focuses include antigen/adjuvant selection, biomaterial-based delivery, and the impact of nanoscale properties on vaccine performance. It also discusses the interplay between the tumor microenvironment and nanovaccine responses alongside ongoing clinical trials, aiming to guide researchers/clinicians in optimizing therapeutic outcomes. AbstractCancer nanovaccines represent a promising frontier in cancer immunotherapy, utilizing nanotec...
Source: Small - May 2, 2024 Category: Nanotechnology Authors: Nimeet Desai,
Vivek Chavda,
Thakur Raghu Raj Singh,
Nanasaheb D. Thorat,
Lalitkumar K. Vora Tags: Review Source Type: research
Concomitant human papillomavirus (HPV) vaccination and screening for elimination of HPV and cervical cancer
In conclusion, concomitant HPV vaccination and HPV screening appears to be a realistic option for faster cervical cancer elimination. Clinicaltrials.gov identifier: NCT04910802; EudraCT number: 2020-001169-34.PMID:38693149 | DOI:10.1038/s41467-024-47909-x (Source: Cancer Control)
Source: Cancer Control - May 1, 2024 Category: Cancer & Oncology Authors: Laila Sara Arroyo M ühr Andrea Gini Emel Yilmaz Sadaf S Hassan Camilla Lagheden Emilie Hultin Ainhoa Garcia Serrano Agustin E Ure Helena Andersson Roxana Merino K Miriam Elfstr öm Iacopo Baussano Joakim Dillner Source Type: research
Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial
Lancet HIV. 2024 May;11(5):e285-e299. doi: 10.1016/S2352-3018(24)00036-5.ABSTRACTBACKGROUND: An effective HIV vaccine will most likely need to have potent immunogenicity and broad cross-subtype coverage. The aim of the HIV Vaccine Trials Network (HVTN) 124 was to evaluate safety and immunogenicity of a unique polyvalent DNA-protein HIV vaccine with matching envelope (Env) immunogens.METHODS: HVTN 124 was a randomised, phase 1, placebo-controlled, double-blind study, including participants who were HIV seronegative and aged 18-50 years at low risk for infection. The DNA vaccine comprised five plasmids: four copies expressin...
Source: Cancer Control - May 1, 2024 Category: Cancer & Oncology Authors: Ian Frank Shuying S Li Nicole Grunenberg Edgar T Overton Samuel T Robinson Hua Zheng Kelly E Seaton Jack R Heptinstall Mary A Allen Kenneth H Mayer Daniel A Culver Michael C Keefer Sri Edupuganti Michael N Pensiero Vijay L Mehra Stephen C De Rosa Daryl E Source Type: research
Vaccination with antigenically complex hemagglutinin mixtures confers broad protection from influenza disease
Sci Transl Med. 2024 May;16(745):eadj4685. doi: 10.1126/scitranslmed.adj4685. Epub 2024 May 1.ABSTRACTCurrent seasonal influenza virus vaccines induce responses primarily against immunodominant but highly plastic epitopes in the globular head of the hemagglutinin (HA) glycoprotein. Because of viral antigenic drift at these sites, vaccines need to be updated and readministered annually. To increase the breadth of influenza vaccine-mediated protection, we developed an antigenically complex mixture of recombinant HAs designed to redirect immune responses to more conserved domains of the protein. Vaccine-induced antibodies wer...
Source: Cancer Control - May 1, 2024 Category: Cancer & Oncology Authors: Zhaochen Luo Hector A Miranda Kaitlyn N Burke M Ariel Spurrier Madison Berry Erica L Stover Rachel L Spreng Greg Waitt Erik J Soderblom Andrew N Macintyre Kevin Wiehe Nicholas S Heaton Source Type: research
Structure-activity relationship in NOD2 agonistic muramyl dipeptides
Eur J Med Chem. 2024 Apr 20;271:116439. doi: 10.1016/j.ejmech.2024.116439. Online ahead of print.ABSTRACTNucleotide-binding oligomerization domain 2 (NOD2) is a receptor of the innate immune system that is capable of perceiving bacterial and viral infections. Muramyl dipeptide (MDP, N-acetyl muramyl L-alanyl-d-isoglutamine), identified as the minimal immunologically active component of bacterial cell wall peptidoglycan (PGN) is recognized by NOD2. In terms of biological activities, MDP demonstrated vaccine adjuvant activity and stimulated non-specific protection against bacterial, viral, and parasitic infections and cancer...
Source: European Journal of Medicinal Chemistry - May 1, 2024 Category: Chemistry Authors: Aarzoo Kamboj Madhuri T Patil Nikolai Petrovsky Deepak B Salunke Source Type: research
Structure-activity relationship in NOD2 agonistic muramyl dipeptides
Eur J Med Chem. 2024 Apr 20;271:116439. doi: 10.1016/j.ejmech.2024.116439. Online ahead of print.ABSTRACTNucleotide-binding oligomerization domain 2 (NOD2) is a receptor of the innate immune system that is capable of perceiving bacterial and viral infections. Muramyl dipeptide (MDP, N-acetyl muramyl L-alanyl-d-isoglutamine), identified as the minimal immunologically active component of bacterial cell wall peptidoglycan (PGN) is recognized by NOD2. In terms of biological activities, MDP demonstrated vaccine adjuvant activity and stimulated non-specific protection against bacterial, viral, and parasitic infections and cancer...
Source: European Journal of Medicinal Chemistry - May 1, 2024 Category: Chemistry Authors: Aarzoo Kamboj Madhuri T Patil Nikolai Petrovsky Deepak B Salunke Source Type: research
Cerebellar symptomatology following Covid-19 vaccination reveals breast cancer
Background: There are various Covid-19 post-vaccination neurological disorders reported but they are still not fully understood. On the other hand, cancer patients can develop neurological disorders due to autoimmune response targeting normal neural tissues such as paraneoplastic cerebellar degeneration. Seronegative and seropositive patients with paraneoplastic cerebellar degeneration have similar clinical presentation. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - May 1, 2024 Category: Neurology Authors: F. Trpcheski, A. Angelova, G. Hristovska, G. Novotni Source Type: research
Post-Radiotherapy Dysphagia in Head and Neck Cancer: Current Management by Speech-Language Pathologists
Opinion statementDysphagia, difficulty in eating and drinking, remains the most common side effect of radiotherapy treatment for head and neck cancer (HNC) with devastating consequences for function and quality of life (QOL). Over the past decade, 5-year survival has improved due to multiple factors including treatment advances, reduction in smoking, introduction of the human papillomavirus (HPV) vaccine and more favourable prognosis of HPV-related cancers. Increased prevalence of HPV-positive disease, which tends to affect younger individuals, has led to an elevated number of people living for longer with the sequelae of ...
Source: Current Treatment Options in Oncology - May 1, 2024 Category: Cancer & Oncology Source Type: research
Optimizing Communication on HPV Vaccination to Parents of 11- to 14-Year-Old Adolescents in France: A Discrete Choice Experiment
DiscussionUsing DCEs to elicit parents ’ preferences around communication messages, notably on cancer prevention, vaccine coverage and information about vaccine safety, could help to optimize HPV vaccination promotion efforts. (Source: The Patient - Patient-Centered Outcomes Research)
Source: The Patient - Patient-Centered Outcomes Research - May 1, 2024 Category: International Medicine & Public Health Source Type: research
ER-associated degradation adapter Sel1L is required for CD8 < sup > + < /sup > T cell function and memory formation following acute viral infection
Cell Rep. 2024 Apr 29;43(5):114156. doi: 10.1016/j.celrep.2024.114156. Online ahead of print.ABSTRACTThe maintenance of antigen-specific CD8+ T cells underlies the efficacy of vaccines and immunotherapies. Pathways contributing to CD8+ T cell loss are not completely understood. Uncovering the pathways underlying the limited persistence of CD8+ T cells would be of significant benefit for developing novel strategies of promoting T cell persistence. Here, we demonstrate that murine CD8+ T cells experience endoplasmic reticulum (ER) stress following activation and that the ER-associated degradation (ERAD) adapter Sel1L is indu...
Source: Cancer Control - April 30, 2024 Category: Cancer & Oncology Authors: Luis O Correa-Medero Shayna E Jankowski Hanna S Hong Nicholas D Armas Aditi I Vijendra Mack B Reynolds Garrett M Fogo Dominik Awad Alexander T Dils Kantaro A Inoki Reid G Williams Annabelle M Ye Nadezhda Svezhova Francisco Gomez-Rivera Kathleen L Collins Source Type: research
Innate immune activation restricts priming and protective efficacy of the radiation-attenuated PfSPZ malaria vaccine
JCI Insight. 2024 Apr 30:e167408. doi: 10.1172/jci.insight.167408. Online ahead of print.ABSTRACTA systems analysis was conducted to determine the potential molecular mechanisms underlying differential immunogenicity and protective efficacy results of a clinical trial of the radiation-attenuated whole sporozoite PfSPZ Vaccine in African infants. Innate immune activation and myeloid signatures at pre-vaccination baseline correlated with protection from Pf parasitemia in placebo controls. These same signatures were associated with susceptibility to parasitemia among infants who received the highest and most protective PfSPZ ...
Source: Cancer Control - April 30, 2024 Category: Cancer & Oncology Authors: Leetah Senkpeil Jyoti Bhardwaj Morgan R Little Prasida Holla Aditi Upadhye Elizabeth M Fusco Phillip A Swanson Ii Ryan E Wiegand Michael D Macklin Kevin Bi Barbara J Flynn Ayako Yamamoto Erik L Gaskin D Noah Sather Adrian L Oblak Edward Simpson Hongyu Gao Source Type: research
Molecules, Vol. 29, Pages 2073: Therapeutic Applications of Nanomedicine: Recent Developments and Future Perspectives
Greish
The concept of nanomedicine has evolved significantly in recent decades, leveraging the unique phenomenon known as the enhanced permeability and retention (EPR) effect. This has facilitated major advancements in targeted drug delivery, imaging, and individualized therapy through the integration of nanotechnology principles into medicine. Numerous nanomedicines have been developed and applied for disease treatment, with a particular focus on cancer therapy. Recently, nanomedicine has been utilized in various advanced fields, including diagnosis, vaccines, immunotherapy, gene delivery, and tissue engineering. Mul...
Source: Molecules - April 30, 2024 Category: Chemistry Authors: Farah Rehan Mingjie Zhang Jun Fang Khaled Greish Tags: Review Source Type: research
Anything that can go wrong: cytotoxic cells and their control of Epstein-Barr virus
Rev Alerg Mex. 2024 Feb 1;71(1):29-39. doi: 10.29262/ram.v71i1.1276.ABSTRACTEpstein-Barr virus (EBV) is an gamma of herpes virus affecting exclusively humans, was the first oncogenic virus described and is associated with over seven different cancers. Curiously, the exchange of genes during viral infections has enabled the evolution of other cellular organisms, favoring new functions and the survival of the host. EBV has been co-evolving with mammals for hundreds of millions of years, and more than 95% of adults have been infected in one moment of their life. The infection is acquired primarily during childhood, in most ca...
Source: Cancer Control - April 29, 2024 Category: Cancer & Oncology Authors: Arturo Guti érrez-Guerrero Sara Elva Espinosa-Padilla Sa úl Oswaldo Lugo-Reyes Source Type: research
Accelerate vaccine development using seamless phase 2/3 trial designs
CONCLUSION: The seamless design proves to be a compelling strategy for vaccine development, given its versatility in early stopping, re-estimating sample sizes, and shortening trial durations.PMID:38682812 | DOI:10.1080/14760584.2024.2348612 (Source: Cancer Control)
Source: Cancer Control - April 29, 2024 Category: Cancer & Oncology Authors: Jia-Ying Yang Guo-Chun Li Ying Yuan Source Type: research
